摘要
新近发现的转录因子DREAM(downstreamregulatoryelementantagonistmodulator)可结合到基因(包括PPD、Hrk、cfos等)的DRE(downstreamregulatoryelement)位点,抑制基因转录。它是第一个已知的可以直接与DNA结合发挥转录抑制作用的Ca2+结合蛋白,为Ca2+调节基因表达除蛋白激酶/磷酸酶这条主要通路外提供了另一条通路。由于DREAM与另两个研究小组发现的蛋白calsenilin和KChIP3实为同一种物质,所以DREAM具有PS(presenilin)作用蛋白、Kv4通道调节蛋白和转录因子的多重功能特性。本文将就DREAM的分布、功能及其调控、DREAM与疼痛的关系作简要综述。
A newly found transcription iactor-DHEAM can bind speclhcally with downstream regulatory element of genes, such as PPD, Hrk and c-Fos, and repress gene expression. It represents the first known Ca^2＋ binding protein to function as a DNA-binding transcription regulator. This provides a new mechanism of Ca^2＋ dependent regulation of gene expression in addition to protein kinase/phosphatase signaling pathway. In fact, DREAM, calsenilin and KChIP3, which are identified by different laboratories, are the same protein. So DREAM is a muhifunctional protein, including PS interacting protein, Kv4 reguratory protein and transcription factor. The distribution, function and regulation of DREAM, as well as relationship between DREAM and pain, are reviewed in the present article.
出处
《生理科学进展》
CAS
CSCD
北大核心
2005年第3期199-203,共5页
Progress in Physiological Sciences
基金
国家自然科学基金(30470550)
北京市自然科学基金(5052019)
国家中医药管理局(0405JP05)资助课题
